PG4 vaccine + PA-001

**PG4 vaccine + PA-001** is an experimental combination therapy under clinical investigation primarily as a **multivalent pneumococcal vaccine formulation with an adjuvant**. PG4 vaccine consists of a next-generation pneumococcal conjugate vaccine developed to provide immunization against *Streptococcus pneumoniae*. PA-001 acts as an adjuvant, included at varying doses to enhance the immune response to the vaccine. The combination is being compared to existing pneumococcal vaccines (e.g., 20vPnC/Prevnar 20, PCV15) and studied both for its safety and immunogenicity in adults and infants. Both components are being developed by Pfizer, which leads all corresponding clinical research studies. The combination is in early-phase clinical development, with no marketing authorization. Dosing involves intramuscular injection, with regimens and booster schedules under evaluation. The mechanism of action is immune system activation against Streptococcus pneumoniae polysaccharide antigens via conjugate technology, potentiated by the adjuvant PA-001[1][2][3].